CSF3R and chronic neutrophilic leukemia: The rationale for the use of dasatinib in CNL stems from the demonstration of the in vitro sensitivity of CNL lines harboring truncating CSF3R mutations to SRC kinase inhibition (20); however, no data on the in vivo efficacy of dasatinib are available.